Once-daily tobramycin therapy in lower respiratory tract infections.
In a multicenter Italian study of 104 adult patients with severe bacterial lower respiratory tract infections, the safety and efficacy of a regimen of high dose, once-daily tobramycin alone or in combination with antipseudomonas betalactams was assessed. The overall bacteriological response was an elimination of the original pathogen in 70% of the patients while the overall clinical response mirrored the bacteriological results with a successful clinical outcome in 78% of patients. Adverse experiences were, in general, few and mild without oto- or nephrotoxicity. The once-daily, high dose regimen of tobramycin proved to be a safe and efficacious therapy for severe lower respiratory tract infections in adult patients.
Grassi
C
C
Clinica Tisiologica e Malattie dell'Apparato Respiratorio, Università, Pavia, Italy.
Ginesu
F
F
Pozzi
E
E
Rimoldi
R
R
Crimi
N
N
Periti
P
P
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007558:Italy; D007769:Lactams; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014031:Tobramycin / Q000008:administration & dosage*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D007769:Lactams; D014031:Tobramycin